Lack of interleukin‐6 in the tumor microenvironment augments type‐1 immunity and increases the efficacy of cancer immunotherapy

@inproceedings{Ohno2017LackOI,
  title={Lack of interleukin‐6 in the tumor microenvironment augments type‐1 immunity and increases the efficacy of cancer immunotherapy},
  author={Yosuke Ohno and Yujiro Toyoshima and Hideaki Yurino and Norikazu Monma and Huihui Xiang and Kentaro Sumida and Shun Kaneumi and Satoshi Terada and Shinichi Hashimoto and Kazuho Ikeo and Shigenori Homma and Hideki Kawamura and Norihiko Takahashi and Akinobu Taketomi and Hidemitsu Kitamura},
  booktitle={Cancer science},
  year={2017}
}
Conquering immunosuppression in tumor microenvironments is crucial for effective cancer immunotherapy. It is well known that interleukin (IL)-6, a pleiotropic cytokine, is produced in the tumor-bearing state. In the present study, we investigated the precise effects of IL-6 on antitumor immunity and the subsequent tumorigenesis in tumor-bearing hosts. CT26 cells, a murine colon cancer cell line, were intradermally injected into wild-type and IL-6-deficient mice. As a result, we found that tumor… CONTINUE READING
3
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity

VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Interferon - g - induced activation of JAK 1 and JAK 2 suppresses tumor cell susceptibility to NK cells through upregulation of PD - L 1 expression

  • R Bellucci, A Martin, D Bommarito
  • Oncoimmunology
  • 2015